alexa Efficacy and Tolerance of Interferon β Plus Riba
ISSN: 2167-0889

Journal of Liver
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Efficacy and Tolerance of Interferon β Plus Ribavirin Treatment for Chronic Hepatitis C Patients with Depression or Thrombocytopenia Comparison with Pegylated Interferon α Plus Ribavirin Treatment

Hiroaki Ikezaki, Norihiro Furusyo*, Eiichi Ogawa, Motohiro Shimizu, Satoshi Hiramine, Kazuya Ura, Fujiko Mitsumoto, Kouji Takayama, Kazuhiro Toyoda, Masayuki Murata and Jun Hayashi
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan
Corresponding Author : Norihiro Furusyo
Department of General Internal Medicine
Kyushu University Hospital, 3-1-1 Maidashi
Higashi-ku, Fukuoka, 812-8582, Japan
Tel: +81-92-642-5909
Fax: +81-92-642-5916
E-mail: [email protected]
Received April 03, 2014; Accepted April 22, 2014; Published May 05, 2014
Citation: Ikezaki H, Furusyo N, Ogawa E, Shimizu M, Hiramine S, et al. (2014) Efficacy and Tolerance of Interferon β Plus Ribavirin Treatment for Chronic Hepatitis C Patients with Depression or Thrombocytopenia Comparison with Pegylated Interferon α Plus Ribavirin Treatment. J Liver 3:155. doi: 10.4172/2167-0889.1000155
Copyright: © 2014 Ikezaki H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Objective: Limited data has been reported comparing natural human interferon β (nIFNβ) and pegylated IFN-α (PEG-IFNα) when Ribavirin (RBV) is combined. This case-control study was done to compare the efficacy and adverse effects of a combination treatment of nIFNβ or PEG-IFNα plus RBV for chronic hepatitis C patients.

Methods: Sixty patients with chronic hepatitis C, 42 infected with hepatitis C virus (HCV) genotype 1 and 18 infected with genotype 2, were treated with nIFNβ plus RBV. Of them, 23 (38.3%) suffered pre-treatment severe depression. Their data was compared with 60 undepressed patients treated with a combination of PEG-IFNα plus RBV. nIFNβ was given intravenously and PEG-IFNα was injected subcutaneously.

Results: Sustained virological response (undetectable HCV RNA at 24 weeks after the end of treatment) did not significantly differ between the nIFNβ and PEG-IFNα treated patients (genotype 1, 21.4% vs. 33.3%, P=0.328; genotype 2, 72.2% vs. 88.9%, respectively, P=0.402). None of the nIFNβ treated patients showed exacerbation of depression, while 7 (11.7%) of 60 PEG-IFNα treated patients developed severe depression or malaise. The platelet count of nIFNβ treated patients increased to higher than baseline after week 8, but the platelet count of PEG-IFNα treated patients decreased throughout the treatment. There were significant differences of the changes of platelet counts between the both groups throughout the treatment (all P<0.001).

Conclusion: nIFNβ plus RBV treatment was well tolerated by chronic hepatitis C patients with depression or thrombpcytopenia.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords